> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rybrevant’s Regulatory Review Period Determined
- URL: https://www.fdaweb.com/rybrevants-regulatory-review-period-determined/
- Published: 2024-02-26T12:00:00.000Z
- Updated: 2026-09-14T14:23:49.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156429

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Janssen Biotech’s Rybrevant (amivantamab-vmjw), indicated for treating adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations. The regulatory review period is 1,284 days, of which 1,105 days occurred during the testing phase and 179 days during the approval phase. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-03961.pdf?ref=fdaweb.com).